| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lipella Pharmaceuticals Inc.
$0
-0.03 (-21.54%)
F 10Pipeline Score Richly Valued Pharma · Clinical
Market Cap
10.54 M
EPS
-4.11
P/E Ratio
-
Value Trade
0.04
0 %
Week
0 %
1 Month
0 %
3 Month
0 %
6 Month
0 %
5 Year
-95.8 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
202.00
52 Week Range
null-null
% held by Insiders
6.53 %
% held by Institutions
1.41 %
Enterprise Value
6.34 M
Total Shares
4.47 M
Short %
2.4 %
Float Shares
3.33 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-12-31 | LP-310 | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-12-31 | LP-310 | Phase 2 data readout | Phase 2 | — | – | – | – |
2025-12-31 | LP-310 | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
F10
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCapLipella Pharmaceuticals Inc. has significant pipeline risk (10/100), with $86M risk-adjusted pipeline value, led by LP-10 in Hemorrhagic Cystitis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LP-10 Small molecule Completed | Hemorrhagic Cystitis | Phase 2 | NCT03129126 | 14% | $86M | COMPLETED | 13 | - | - | Sep 29, 2023 | - | Dec 11, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LP-10 | oral lichen planus | Phase 2a | 2025-09-18 | safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores Read More | Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus Read More | |
LP-10 | oral lichen planus | Phase 2a | 2025-09-18 | safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores Read More | Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus Read More | |
LP-10 | oral lichen planus | Phase 2a | 2025-09-18 | safety profile: met its primary safety endpoint; efficacy outcomes: statistically significant improvements across all efficacy measures at the 4-week timepoint; dose groups: All three dose groups (0.25 mg, 0.5 mg, and 1.0 mg) demonstrated statistically significant improvements at Week 4 (all p<0.05); IGA: showed clear reductions in ulceration and erythema scores Read More | Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus Read More |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIPO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LIPO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How LIPO ranks across every disease it competes inCompetitive Position is a premium feature
See how LIPO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial